Search results for "SART"

showing 10 items of 212 documents

Angiotensin II contractile effects in mouse colon: role for pre- and post-junctional AT1A receptors

2013

Aim This study investigates whether a local renin–angiotensin system (RAS) exists in mouse colon and whether angiotensin II (Ang II) may play a role in the regulation of the contractile activity. Methods Isometric recordings were performed in vitro on the longitudinal muscle of mouse proximal and distal colon. Transcripts encoding for RAS components were investigated by RT-PCR. Results Ang II caused, in both preparations, a concentration-dependent contractile effect, antagonized by losartan, AT1 receptor antagonist, but not by PD123319, AT2 receptor antagonist. The combination of losartan plus PD123319 caused no change on the Ang II-induced contraction than losartan alone. Tetrodotoxin, neu…

Malemedicine.medical_specialtyColonPhysiologymedicine.drug_classMuscarinic AntagonistsBiologyReceptor Angiotensin Type 1Renin-Angiotensin SystemMicechemistry.chemical_compoundOrgan Culture TechniquesInternal medicineMuscarinic acetylcholine receptormedicineAnimalsReceptorAngiotensin II receptor type 1Reverse Transcriptase Polymerase Chain ReactionAngiotensin IIAntagonistMuscle Smoothangiotensin II AT1 receptors AT2 receptors enteric neurones mouse colon muscle contraction.Receptor antagonistAngiotensin IIElectrophysiologyMice Inbred C57BLEndocrinologyLosartanchemistryHexamethoniumhormones hormone substitutes and hormone antagonistsMuscle Contractionmedicine.drug
researchProduct

Could HLA-DQ suggest why some patients have olmesartan-related diarrhea and others don't?

2015

Malemedicine.medical_specialtyHepatologybusiness.industryDuodenumGastroenterologyGastroenterologyDiarrheaCeliac Diseasemedicine.anatomical_structureIntestinal mucosaInternal medicineHLA-DQmedicineDuodenumHumansFemalemedicine.symptomIntestinal MucosabusinessOlmesartanImmunosuppressive Agentsmedicine.drugThe American journal of gastroenterology
researchProduct

Impaired cortico-bulbar tract function in dysarthria due to hemispheric stroke. Functional testing using transcranial magnetic stimulation.

1997

We investigated cortico-lingual and cortico-orofacial tract function utilizing transcranial magnetic stimulation in 18 consecutive patients with dysarthria due to hemispheric stroke. Delayed responses (conduction time > mean + 2.5 SD of that of 43 controls) or absent responses were considered abnormal. In all patients, motor-cortex stimulation of the lesion side demonstrated absent (13 patients) or delayed (five patients) responses to the tongue bilaterally (17 patients) or unilaterally (one patient). In 14 patients the contralateral orofacial responses were either absent (13 patients) or delayed (one patient). According to the electrophysiological findings, all lesions revealed by CT or MR…

Malemedicine.medical_specialtyInternal capsulemedicine.medical_treatmentNeural ConductionDysarthriaTongueInternal medicinemedicineHumansStrokeAgedAged 80 and overPyramidal tractsCerebral infarctionDysarthriaMotor CortexCerebral InfarctionMiddle Agedmedicine.diseaseTranscranial Magnetic StimulationElectric StimulationSurgeryTranscranial magnetic stimulationCerebrovascular DisordersFacial Nervemedicine.anatomical_structureCorticospinal tractCardiologyFemaleNeurology (clinical)medicine.symptomPsychologyMotor cortexBrain : a journal of neurology
researchProduct

Endoscopic hemostasis followed by preventive transarterial embolization in high-risk patients with bleeding peptic ulcer: 5-year experience

2019

Abstract Background Upper gastrointestinal bleeding (UGIB) due to peptic ulcer disease is one of the leading causes of death in patients with non-variceal bleeding, resulting in up to 10% mortality rate, and the patient group at high risk of rebleeding (Forrest IA, IB, and IIA) often requires additional therapy after endoscopic hemostasis. Preventive transarterial embolization (P-TAE) after endoscopic hemostasis was introduced in our institution in 2014. The aim of the study is an assessment of the intermediate results of P-TAE following primary endoscopic hemostasis in patients with serious comorbid conditions and high risk of rebleeding. Methods During the period from 2014 to 2018, a tota…

Malemedicine.medical_specialtyLeft gastric arteryTransarterial embolizationmedicine.medical_treatmentlcsh:SurgeryNon-variceal gastrointestinal bleeding030230 surgeryGastroduodenal artery03 medical and health sciences0302 clinical medicineRecurrencePreventivemedicine.arterymedicineHumansEmbolizationAgedAged 80 and overbusiness.industryMortality rateHemostasis Endoscopiclcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RD1-811lcsh:RC86-88.9Middle Agedmedicine.diseaseEmbolization TherapeuticSurgeryPeptic Ulcer HemorrhageTreatment OutcomeEmergency MedicineFemale030211 gastroenterology & hepatologySurgeryFresh frozen plasmaUpper gastrointestinal bleedingPacked red blood cellsRockall scorebusinessResearch ArticleWorld Journal of Emergency Surgery
researchProduct

Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Misse…

2016

Background Central aortic blood pressure (CBP) and CBP-derived parameters are independent predictors of cardiovascular risk. Angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors plus calcium channel blockers are the recommended first-line treatments in hypertensive diabetic patients; however, the effect in reducing CBP when a dose is skipped has not been established yet. The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine (OLM/AML) provides equal efficacy and safety as the perindopril/AML (PER/AML) combination in reducing CBP, augmentation index (AIx), and pulse wave velocity (PWV) when a drug dose is missed. Methods In this no…

Malemedicine.medical_specialtyMissed DoseFixed-dose combinationUrologyTetrazolesolmesartanPulse Wave Analysisamlodipine030204 cardiovascular system & hematologyNO03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal MedicinemedicinePerindoprilHumans030212 general & internal medicineAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilPulse wave velocityAgedbusiness.industryImidazolesblood pressureMiddle Agedantihypertensive agentsBlood pressureDiabetes Mellitus Type 2Hypertensiondiabetes mellitusAortic pressureFemaleperindoprilOlmesartanbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

Clinical presentation of strokes confined to the insula: a systematic review of literature

2021

Abstract Background and purpose The insular cortex serves a wide variety of functions in humans, ranging from sensory and affective processing to high-level cognition. Hence, insular dysfunction may result in several different presentations. Ischemic strokes limited to the insular territory are rare and deserve a better characterization, to be quickly recognized and to receive appropriate treatment (e.g. thrombolysis). Methods We reviewed studies on patients with a first-ever acute stroke restricted to the insula. We searched in the Medline database the keywords “insular stroke” and “insular infarction”, to identify previously published cases. Afterwards, the results were divided depending …

Malemedicine.medical_specialtyNeurologySensory systemReview ArticleDermatology030204 cardiovascular system & hematologyInsular cortexbehavioral disciplines and activities03 medical and health sciencesDysarthria0302 clinical medicinePhysical medicine and rehabilitationAphasiaAphasiamedicineHumansSpeechCerebrovascular diseaseStrokeNeuroradiologyInsular syndromesCerebral CortexInsular stroke Insular dysfunction Insular syndromes Cerebrovascular diseasebusiness.industryDysarthriaGeneral Medicinemedicine.diseaseStrokePsychiatry and Mental healthnervous systembehavior and behavior mechanismsInsular strokeSettore MED/26 - NeurologiaFemaleNeurology (clinical)medicine.symptomInsular dysfunctionbusinessInsulapsychological phenomena and processes030217 neurology & neurosurgeryNeurological Sciences
researchProduct

Dysarthria and lacunar stroke

1996

We investigated the supranuclear tracts involved in speech production in 8 patients with dysarthria associated with a single lacunar stroke.Magnetic resonance imaging revealed the lesion site in 7 out of 8 patients. We tested corticobulbar tract function using transcranial magnetic stimulation and demonstrated impairment of the corticolingual projections in all the patients and in 5 patients impairment of the corticofacial projections. Sensory function in the oral cavity was impaired in 1 out of 8 patients.99m Tc hexamethyl-propylene amine oxime-single-photon emission computerized tomography (HMPAO-SPECT) imaging, performed in 5 patients, showed cerebellar diaschisis in 1, suggesting additi…

Malemedicine.medical_specialtyPathologyLacunar strokemedicine.medical_treatmentNeurological disorderDysarthriaCerebellumInternal medicinemedicineHumansSpeechStrokeAgedmedicine.diagnostic_testbusiness.industryCerebral infarctionDysarthriaMagnetic resonance imagingMiddle Agedmedicine.diseasenervous system diseasesTranscranial magnetic stimulationCerebrovascular DisordersCardiologyCorticobulbar tractNeurology (clinical)medicine.symptombusinessNeurology
researchProduct

Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo

2011

Aims In vitro studies suggest that mast cell chymase (MCP) is more important than angiotensin-converting enzyme (ACE) for generating angiotensin II (Ang II) within the cardiovascular system. We investigated in vivo the relative contributions of ACE and MCP to leucocyte recruitment induced by endogenously generated Ang II. Methods and results Exposure of the murine cremasteric microcirculation of C57BL/6 mice to Ang I (100 nM for 4 h) induced leucocyte–endothelium interactions. Either losartan (an Ang II receptor-1 antagonist, AT1) or enalapril (an ACE inhibitor), but not chymostatin (a chymase inhibitor), inhibited Ang I-induced responses. Mast cell degranulation with compound 48/80 (CMP48/…

Malemedicine.medical_specialtyPhysiologymedicine.drug_classReceptor expressionPeptidyl-Dipeptidase AReceptor Angiotensin Type 1MiceChymasesCell MovementPhysiology (medical)Internal medicineLeukocytesmedicineAnimalsp-Methoxy-N-methylphenethylamineMast CellsMast cell stabilizerEnalaprilAngiotensin II receptor type 1ChemistryAngiotensin IIChymaseAngiotensin IIMice Inbred C57BLEndocrinologyLosartanACE inhibitorcardiovascular systemAngiotensin ICardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsmedicine.drugCardiovascular Research
researchProduct

Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study

2018

Background: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubilril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. Methods and results: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30 days after initiation of sacubitril/valsartan therapy. A mixed-effects model …

Malemedicine.medical_specialtyTime FactorsTetrazolesPilot ProjectsWalk Test030204 cardiovascular system & hematologySacubitrilCohort Studies03 medical and health sciencesAngiotensin Receptor AntagonistsElectrocardiography0302 clinical medicineInternal medicineExercise capacityMedicineHumans6-minute walk test030212 general & internal medicineEnalaprilProspective StudiesSacubitril/valsartanAgedAged 80 and overEjection fractionExercise Tolerancebusiness.industryAminobutyratesBiphenyl CompoundsExercise capacityMiddle Agedmedicine.diseaseHeart failure with reduced ejection fractionDrug CombinationsTreatment OutcomeValsartanHeart failureCardiologyValsartanFemaleCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study

2017

Malemedicine.medical_specialtyTreatment outcomeTetrazolesPilot Projects030204 cardiovascular system & hematology030226 pharmacology & pharmacyAngiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeprilysinAgedHeart FailureExercise ToleranceEjection fractionbusiness.industryAminobutyratesBiphenyl CompoundsStroke VolumeGeneral MedicineExercise capacitymedicine.diseaseDrug CombinationsTreatment OutcomeHeart failureCardiologyValsartanFemaleNeprilysinbusinessSacubitril ValsartanRevista Española de Cardiología (English Edition)
researchProduct